Amorcyte, Inc.
http://www.amorcyte.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amorcyte, Inc.
Deals Shaping the Medical Industry (09/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
NeoStem raises $16.5M as it continues to shift its focus to cell therapy
NeoStem, the New York-based cell therapy company, plans to raise $16.5 million through the sale of 13.8 million share-and-warrant units at $1.20 per unit, a considerable discount to the 18 July stock closing price of $1.32.
NeoStem expands into cardiovascular space with $18 million Amorcyte buy
Stem cell specialist NeoStem has agreed to purchase Amorcyte, a cardiovascular stem cell therapy developer, a move which will give it access to the cardiovascular therapy market. Amorcyte's lead product, AMR-001, is about to start a Phase II trial in acute myocardial infarction (AMI).
Amorcyte Inc.
Amorcyte is intent on developing patients' own enriched bone-marrow stem cells as a treatment for cardiovascular disease. The idea is to infuse the stem cells into the heart a week or so after a severe heart attack, where they will linger and help restore damaged tissue. Results of a Phase I clinical trial recently reported at the scientific session of the American College of Cardiology conference showed the treatment was safe, and yielded insight into the minimum dosage necessary to generate a beneficial effect.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice